Universität zu Köln

Journal Article

Chyla, Brenda, Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Puvvada, Soham, Wendtner, Clemens, Davids, Matthew S., Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Wierda, William and Hallek, Michael (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. Leuk. Lymphoma, 58. S. 234 - 236. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trneny, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Guenter, Humphrey, Kathryn, Stilgenbauer, Stephan, Boettcher, Sebastian, Brueggemann, Monika, Hallek, Michael, Kneba, Michael and van Dongen, Jacques J. M. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133 (5). S. 494 - 498. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Rawstron, Andy, Fazi, Claudia, Villamor, Neus, Delgado, Julio ORCID: 0000-0002-5157-4376, Letestu, Remi, Cymbalista, Florence, Palacio, Carlos, Bosch, Francesc ORCID: 0000-0001-9241-2886, De Tute, Ruth M., Liptrot, Stuart, O'Brien, David, Spacek, Martin ORCID: 0000-0001-5250-8218, Dobber, Johan, Kater, Arnon P., Gambell, Peter C., Westerman, David A., Soosapilla, Asha, Mulligan, Stephen P., Lozanski, Gerard, Lin, Ke, Pettitt, Andrew R., Brachtl, Gabi, Egle, Alexander, Williamson, David W., Sanders, Catherine M., Robins, Harlan, Boysen, Justin, Shanafelt, Tait D., Hanson, Curtis A., Jorgensen, Jeffrey L., Wierda, William G., Yuan, Constance, Stetler-Stevenson, Maryalice, Rassenti, Laura, Broome, H. Elizabeth, Kipps, Thomas J., Hauwel, Mathieu, Marinov, Iuri, Craig, Fiona E., Josep, Nomdedeu, Moreno, Carol, Stehlikova, Olga, Doubek, Michael, Pospisilova, Sarka, Kreuzer, Karl-Anton, Hallek, Michael, Hillmen, Peter, Montserrat, Emili and Ghia, Paolo (2014). A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Rawstron, Andy C., Kreuzer, Karl-Anton, Soosapilla, Asha, Spacek, Martin ORCID: 0000-0001-5250-8218, Gambell, Peter, McIver-brown, Neil, Psarra, Katherina, Arroz, Maria, Milani, Raffaella, de la Serna, Javier, Teresa Cedena, M., Jaksic, Ozren, Nomdedeu, Josep F., Moreno, Carol, Rigolin, Gian Matteo, Cuneo, Antonio, Johansen, Preben, Johnsen, Hans Erik ORCID: 0000-0001-8253-2913, Rosenquist, Richard, Niemann, Carsten Utoft, Kern, Wolfgang, Westerman, David A., Trneny, Marek, Mulligan, Stephen P., Hillmen, Peter, Oscier, David G., Hallek, Michael, Ghia, Paolo and Montserrat, Emili (2015). Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Ruchlemer, Rosa, Ben-Ami, Ronen ORCID: 0000-0003-0628-0798, Bar-Meir, Maskit, Brown, Jennifer R., Malphettes, Marion, Mous, Rogier, Tonino, Sanne H., Soussain, Carole, Barzic, Noelie, Messina, Julia A., Jain, Preetesh ORCID: 0000-0003-2735-168X, Cohen, Regev, Hill, Brian, Mulligan, Stephen P., Nijland, Marcel, Herishanu, Yair, Benjamini, Ohad, Tadmor, Tamar, Okamoto, Koh, Arthurs, Benjamin, Gottesman, Batsheva, Kater, Arnon P., Talha, Munir, Eichhorst, Barbara, Korem, Maya, Bogot, Naama, De Boer, Fransien, Rowe, Jacob M. and Lachish, Tamar (2019). Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. Mycoses, 62 (12). S. 1140 - 1148. HOBOKEN: WILEY. ISSN 1439-0507

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Desai, Monali, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod, Gordon, Gary, Hallek, Michael and Wierda, William G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol., 17 (6). S. 768 - 779. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669